SYDNEY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ) today announced that Dustin Haines, Chief Executive Officer, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on 11th December. Presentation DetailsEvent: Life Sciences Virtual Investor ForumDate: Thursday, 11th December Time: 11:30 AM ETWebcast: REGISTER HERE Recent Company Highlights FDA-approved solution EchoSolv AS continued to bui ...

Core Viewpoint - Echo IQ Limited has successfully completed clinical validation for its heart failure clinical decision support software, EchoSolv HF, in collaboration with the Mayo Clinic Platform, marking a significant milestone towards FDA clearance [1][3][9]. Company Summary - Echo IQ Limited is an AI and medical technology company based in Sydney, Australia, focused on improving decision-making in cardiology through AI-driven technology and proprietary software [11]. - The company is preparing to submit for FDA clearance of EchoSolv HF via the 510(k) regulatory pathway, with submission expected in the coming weeks [4][9]. Clinical Validation Details - The clinical validation assessed EchoSolv HF's ability to detect heart failure using an independent dataset of approximately 17,000 echocardiogram studies, achieving a sensitivity of 99.5% and specificity of 91.0% [2][3][8]. - Completion of this validation fulfills the final clinical requirement before the formal FDA submission [3][8]. Market Opportunity - Heart failure is a leading cause of rehospitalization in the US, accounting for 17% of all healthcare expenditure, with a total market size estimated at US$60 billion [5][8]. - It is projected that one in four Americans will develop heart failure in their lifetime, indicating a significant market opportunity for EchoSolv HF [5][8]. Future Plans - Following potential FDA clearance, the company plans to leverage its existing presence in the US market to promote the uptake of EchoSolv HF [6][8]. - A webinar is scheduled for November 26, 2025, where the CEO will discuss the development and progress in the US market [7][9].